{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:26:47Z","timestamp":1787030807503,"version":"build-2736575974"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV) has substantially altered the epidemiology and prognosis of oropharyngeal squamous cell carcinomas (OPSCC), with an increasing incidence in younger patients and markedly improved survival outcomes. This shift presents an increasing clinical challenge: how to safely reduce treatment intensity, while maintaining cure and survival rates and minimizing therapy-related toxicity. Transoral robotic surgery (TORS) has emerged as a pivotal strategy in this context, with multiple clinical trials demonstrating promising outcomes. This review aims to summarize registered clinical trials evaluating TORS in OPSCC, identify existing gaps in the literature, and highlight directions for future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search of\n                      <jats:italic>ClinicalTrials.gov<\/jats:italic>\n                      was conducted between May 2024 and January 2026 using the search terms \u201cTORS\u201d and \u201ctransoral robotic surgery.\u201d The search included completed and analyzed studies, as well as completed but unanalyzed, ongoing or planned studies. Relevant publications were retrieved from databases including\n                      <jats:italic>ClinicalTrials.gov<\/jats:italic>\n                      , PubMed and The Cochrane Library. As this study was based on publicly available literature and trial registries, ethical committee approval was not required.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 51 clinical trials were identified. We retrieved a total of 23 publications and 3 abstracts. Across these studies, TORS demonstrated oncologic outcomes comparable to radiotherapy in early-stage OPSCC, with distinct but generally acceptable toxicity profiles. Several trials supported the feasibility of treatment de-escalation, including reduced-dose or omission of adjuvant radiotherapy in carefully selected HPV-positive patients, without compromising survival outcomes. Emerging evidence from biomarker-driven studies suggests that circulating cell-free HPV DNA (cfHPVDNA) may enable improved risk stratification and guide personalized de-intensification strategies. In addition, optimization studies indicate that advances in perioperative management and robotic technology may further improve functional outcomes, although high-quality evidence remains limited. Five key areas of research were identified, namely the optimization strategies, TORS as an alternative strategy, TORS for de-escalation, biomarker-driven de-escalation, and induction therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Transoral robotic surgery demonstrates favorable oncological and functional outcomes, supporting its role as a de-intensification strategy in carefully selected patients with OPSCC. The integration of robust risk stratification methods, including biomarkers such as circulating cell-free HPV DNA (cfHPVDNA), holds promise for optimizing patient selection and tailoring treatment intensity. Continued advancements in robotic technology, along with the development of refined perioperative pain management strategies, may further enhance surgical precision and postoperative recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1863731","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:04Z","timestamp":1787027344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on completed and ongoing trials investigating TORS in head and neck oncology"],"prefix":"10.3389","volume":"16","author":[{"given":"Annelien","family":"Boonen","sequence":"first","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien","family":"Verstappen","sequence":"additional","affiliation":[{"name":"Katholieke Universiteit Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nuyts","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Clement","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Meulemans","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Di Santo","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Willaert","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auke","family":"van Mierlo","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Menten","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost-Limburg","place":["Genk, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vanclooster","sequence":"additional","affiliation":[{"name":"AZ Sint-Lucas & Volkskliniek","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Neyt","sequence":"additional","affiliation":[{"name":"AZ Sint-Lucas & Volkskliniek","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Vander Poorten","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","unstructured":"Global Cancer Observatory: Cancer Tomorrow"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.4115","article-title":"Survivorship and quality of life in head and neck cancer","volume":"33","author":"Ringash","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV)","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000227184.90514.1a","article-title":"Transoral robotic surgery (TORS) for base of tongue neoplasms","volume":"116","author":"O'Malley","year":"2006","journal-title":"Laryngoscope"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2020.07.006","article-title":"History and acceptance of transoral robotic surgery","volume":"53","author":"Thaler","year":"2020","journal-title":"Otolaryngol Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02755","article-title":"Transoral robotic surgery in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma: ASCO guideline","author":"Holsinger","year":"2025","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2024.3371","article-title":"Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma: secondary analysis of the PATHOS randomized clinical trial","volume":"150","author":"O'Hara","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hed.28057","article-title":"Circulating tumor HPV-DNA in the management of HPV-positive oropharyngeal carcinoma: a systematic review","author":"Chen","year":"2025","journal-title":"Head Neck"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2020.07.017","article-title":"Complications of transoral robotic surgery","volume":"53","author":"Sethi","year":"2020","journal-title":"Otolaryngol Clin North Am"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26625","article-title":"A randomized controlled trial of corticosteroids for pain after transoral robotic surgery","volume":"127","author":"Clayburgh","year":"2017","journal-title":"Laryngoscope"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/00016489.2023.2269998","article-title":"The effect of dexamethasone on functional pain following transoral robotic surgery: a randomized double-blinded clinical trial","volume":"143","author":"Larsen","year":"2023","journal-title":"Acta Otolaryngol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2019.2654","article-title":"A next-generation single-port robotic surgical system for transoral robotic surgery: results from prospective nonrandomized clinical trials","volume":"145","author":"Holsinger","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00119","article-title":"Radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: final results of the ORATOR randomized trial","volume":"42","author":"Nichols","year":"2024","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00119","article-title":"Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial","volume":"42","author":"Nichols","year":"2024","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0461","article-title":"The ORATOR trials have spoken\u2014where do we go from here","volume":"8","author":"Teckie","year":"2022","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0615","article-title":"Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: the ORATOR2 phase 2 randomized clinical trial","volume":"8","author":"Palma","year":"2022","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/lary.30410","article-title":"Dysphagia and QoL 3 years after treatment of oropharyngeal cancer with TORS or radiotherapy","volume":"133","author":"Scott","year":"2023","journal-title":"Laryngoscope"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000531995","article-title":"Survival and swallowing function after primary radiotherapy versus transoral robotic surgery for human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"85","author":"Hughes","year":"2023","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1200\/JCO.2020.38.15_suppl.6578","article-title":"Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: a feasibility study","volume":"38","author":"Gunn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25199","article-title":"Oncologic outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: results of the French Robotic Surgery Group of GETTEC","volume":"40","author":"Doazan","year":"2018","journal-title":"Head Neck"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac130","article-title":"Transoral robotic surgery for recurrent tumors of the upper aerodigestive tract (RECUT): an international cohort study","volume":"114","author":"Hardman","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13742","article-title":"De-escalated adjuvant therapy after transoral robotic surgery for human papillomavirus-related oropharyngeal carcinoma: the Sinai Robotic Surgery (SIRS) trial","volume":"26","author":"Miles","year":"2021","journal-title":"Oncologist"},{"key":"B26","article-title":"Transoral surgery followed by low-dose radiation therapy for HPV-related oropharyngeal cancer: ECOG-ACRIN 3311 final results","volume":"39","author":"Ferris","year":"2021","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.11.021","article-title":"A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx","volume":"106","author":"Swisher-McClure","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2024.0423","article-title":"Transoral robotic surgery and radiation volume deintensification in unknown primary squamous cell carcinoma of the neck: the phase 2 FIND nonrandomized controlled trial","volume":"150","author":"de Almeida","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00324-9","article-title":"De-escalated adjuvant radiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma: the phase 3 DART-HPV randomised controlled trial","volume":"26","author":"Ma","year":"2025","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29739","article-title":"Cell-free human papillomavirus-DNA for monitoring treatment response of head and neck squamous cell carcinoma: systematic review and meta-analysis","volume":"132","author":"Campo","year":"2022","journal-title":"Laryngoscope"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(23)01938-5","article-title":"Prospective evaluation of dynamic changes of cell-free HPV-DNA (cfHPV-DNA) in locoregional HPV-associated (HPV+) oropharyngeal cancer (OPSCC) treated with neoadjuvant chemotherapy and response-stratified treatment","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104957","article-title":"Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck: mature clinical and functional outcomes","volume":"110","author":"Hackman","year":"2020","journal-title":"Oral Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31526","article-title":"Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck","volume":"124","author":"Weiss","year":"2018","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized controlled trial","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e18549","article-title":"Phase II study: induction chemotherapy & transoral surgery as definitive treatment for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): an update and retrospective review of non-study patients","author":"Siegel","year":""},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.04.029","article-title":"High recurrence for HPV-positive oropharyngeal cancer with neoadjuvant radiation therapy to gross disease plus immunotherapy: analysis from a prospective phase Ib\/II clinical trial","volume":"117","author":"Ma","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113437","article-title":"Lidocaine induces apoptosis in head and neck squamous cell carcinoma through activation of bitter taste receptor T2R14","volume":"42","author":"Miller","year":"2023","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.2147\/OTT.S505753","article-title":"Lidocaine as a potential therapeutic agent in colorectal cancer: a study of gene expression and prognosis","author":"Li","year":""},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01966","article-title":"Effect of peritumoral infiltration of local anesthetic before surgery on survival in early breast cancer","volume":"41","author":"Badwe","year":"2023","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2023.3994","article-title":"Comparison of da Vinci single port vs Si systems for transoral robotic-assisted surgery: a review with technical insights","volume":"150","author":"Oberhelman","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106629","article-title":"Transoral robotic surgery in oropharyngeal squamous cell carcinoma: a comparative study between da Vinci Single-Port and da Vinci Xi systems","volume":"148","author":"Costantino","year":"2024","journal-title":"Oral Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26902","article-title":"Transoral robotic surgery (TORS) using the da Vinci Xi: prospective analysis of feasibility, safety, and outcomes","volume":"44","author":"Meulemans","year":"2022","journal-title":"Head Neck"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108434","article-title":"Quality of life outcomes comparing primary transoral robotic surgery (TORS) with primary radiotherapy for early-stage oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis","volume":"50","author":"Gupta","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206039","article-title":"A comprehensive systematic review on functional results, speech and swallowing outcomes after trans-oral robotic surgery for oropharyngeal squamous cell cancer","volume":"13","author":"Guarino","year":"2024","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11480","DOI":"10.1038\/s41598-025-93152-9","article-title":"Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy","volume":"15","author":"Gupta","year":"2025","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/v17030409","article-title":"The role of cf-HPV DNA as an innovative biomarker for predicting the recurrence or persistence of cervical cancer","volume":"17","author":"Poinho","year":"2025","journal-title":"Viruses"},{"key":"B47","article-title":"Pembrolizumab with surgery and radiotherapy for resectable, locally advanced, head and neck squamous cell carcinoma (KEYNOTE-689)","author":"Uppaluri","year":"2025","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1863731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:05Z","timestamp":1787027345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1863731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1863731"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1863731","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1863731"}}